As this clinical-stage biotechnology company focused on developing treatments for complex rare diseases enters the home stretch of its Biologics License Application submission, the coming months will be critical and worth watching closely.
The company we are profiling today is Larimar Therapeutics Inc. (LRMR), and the investigational drug in focus is Nomlabofusp, being developed for Friedreich's ataxia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com